CL2023003114A1 - Régimen de dosificación de anti-ifnar1 para inyección subcutánea - Google Patents

Régimen de dosificación de anti-ifnar1 para inyección subcutánea

Info

Publication number
CL2023003114A1
CL2023003114A1 CL2023003114A CL2023003114A CL2023003114A1 CL 2023003114 A1 CL2023003114 A1 CL 2023003114A1 CL 2023003114 A CL2023003114 A CL 2023003114A CL 2023003114 A CL2023003114 A CL 2023003114A CL 2023003114 A1 CL2023003114 A1 CL 2023003114A1
Authority
CL
Chile
Prior art keywords
ifnar1
subcutaneous injection
dosing regimen
type
disclosure relates
Prior art date
Application number
CL2023003114A
Other languages
English (en)
Spanish (es)
Inventor
Lindholm Catharina
Lin Chia Yen
Tummala Rajendra
Roskos Lorin
Almquist Joachim
Rouse Tomas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=81750490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2023003114(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2023003114A1 publication Critical patent/CL2023003114A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Devices For Medical Bathing And Washing (AREA)
CL2023003114A 2021-04-23 2023-10-19 Régimen de dosificación de anti-ifnar1 para inyección subcutánea CL2023003114A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178739P 2021-04-23 2021-04-23
US202163245285P 2021-09-17 2021-09-17
US202163272851P 2021-10-28 2021-10-28

Publications (1)

Publication Number Publication Date
CL2023003114A1 true CL2023003114A1 (es) 2024-04-19

Family

ID=81750490

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003114A CL2023003114A1 (es) 2021-04-23 2023-10-19 Régimen de dosificación de anti-ifnar1 para inyección subcutánea

Country Status (25)

Country Link
US (4) US20220340669A1 (enExample)
EP (2) EP4114465B1 (enExample)
JP (3) JP7484027B2 (enExample)
KR (2) KR20230166134A (enExample)
CN (2) CN120514844A (enExample)
AU (2) AU2022260531B2 (enExample)
BR (1) BR112023021761A2 (enExample)
CA (1) CA3216387A1 (enExample)
CL (1) CL2023003114A1 (enExample)
CO (1) CO2023015498A2 (enExample)
DK (1) DK4114465T5 (enExample)
ES (1) ES2963757T3 (enExample)
FI (1) FI4114465T3 (enExample)
HR (1) HRP20231255T1 (enExample)
HU (1) HUE063562T2 (enExample)
IL (2) IL327109A (enExample)
LT (1) LT4114465T (enExample)
MX (1) MX2023012465A (enExample)
PL (1) PL4114465T3 (enExample)
PT (1) PT4114465T (enExample)
RS (1) RS64821B1 (enExample)
SI (1) SI4114465T1 (enExample)
SM (1) SMT202300382T1 (enExample)
TW (1) TW202317182A (enExample)
WO (1) WO2022223714A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643237T3 (es) * 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
KR20230110304A (ko) * 2020-11-18 2023-07-21 아스트라제네카 아베 스테로이드 절약
AU2022260544A1 (en) * 2021-04-23 2023-11-30 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
TW202317617A (zh) * 2021-04-23 2023-05-01 瑞典商阿斯特捷利康公司 皮膚紅斑狼瘡之治療
SMT202300382T1 (it) 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea
CN113621063A (zh) * 2021-08-02 2021-11-09 江苏荃信生物医药有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法
EP4713361A1 (en) 2023-05-19 2026-03-25 AstraZeneca AB Treatment of lupus
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044406A1 (en) 2001-03-02 2003-03-06 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
ES2643237T3 (es) * 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2651866C (en) 2006-05-11 2014-10-28 Universiteit Gent Sialoadhesin-related compositions and methods
WO2008070135A2 (en) 2006-12-06 2008-06-12 Medimmune, Llc. Methods of treating systemic lupus erythematosus
CA2692784C (en) 2007-07-12 2018-10-02 The Brigham And Women's Hospital, Inc. Compositions and methods for diagnosing and assessing inflammatory myopathies
AU2008324800B2 (en) 2007-11-05 2014-03-27 Astrazeneca Ab Methods of treating scleroderma
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
US20110287022A1 (en) 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers
KR20110044905A (ko) 2008-08-15 2011-05-02 메리맥 파마슈티컬즈, 인크. 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
SMT201700063T1 (it) 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
CN104603152A (zh) * 2012-06-13 2015-05-06 米迪缪尼有限公司 针对抗i型干扰素受体(ifnar)抗体的固定剂量方案
SI3769781T1 (sl) 2015-08-19 2023-06-30 Astrazeneca Ab Stabilna formulacija proti-IFNAR1
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
SG11202101946YA (en) * 2018-09-18 2021-04-29 I Mab Biopharma Hangzhou Co Ltd Anti-ifnar1 antibodies for treating autoimmune diseases
EP3924383A1 (en) * 2019-02-15 2021-12-22 Astrazeneca AB Type i interferon-mediated disorders
DK4058060T3 (da) 2019-11-11 2025-03-17 Astrazeneca Ab Type i-interferon-hæmning ved systemisk lupus erythematosus
JP2023527054A (ja) 2020-05-29 2023-06-26 アストラゼネカ・アクチエボラーグ Ｉ型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療
TW202237647A (zh) * 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
KR20230110304A (ko) * 2020-11-18 2023-07-21 아스트라제네카 아베 스테로이드 절약
SMT202300382T1 (it) 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea
AU2022260544A1 (en) 2021-04-23 2023-11-30 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
CN113278070B (zh) 2021-04-25 2022-06-14 福州迈新生物技术开发有限公司 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂

Also Published As

Publication number Publication date
DK4114465T3 (da) 2023-10-30
SMT202300382T1 (it) 2024-01-10
TW202317182A (zh) 2023-05-01
IL327109A (en) 2026-05-01
WO2022223714A1 (en) 2022-10-27
JP2026086416A (ja) 2026-05-26
EP4114465B1 (en) 2023-08-30
CO2023015498A2 (es) 2023-11-30
JP7805393B2 (ja) 2026-01-23
AU2022260531B2 (en) 2024-03-07
RS64821B1 (sr) 2023-12-29
JP7484027B2 (ja) 2024-05-15
ES2963757T3 (es) 2024-04-01
CA3216387A1 (en) 2022-10-27
US20220340669A1 (en) 2022-10-27
CN120514844A (zh) 2025-08-22
BR112023021761A2 (pt) 2023-12-26
JP2024511227A (ja) 2024-03-12
AU2024201743A1 (en) 2024-04-04
EP4114465A1 (en) 2023-01-11
KR20230166134A (ko) 2023-12-06
FI4114465T3 (fi) 2023-10-31
US12060429B2 (en) 2024-08-13
DK4114465T5 (da) 2024-07-22
LT4114465T (lt) 2023-11-10
MX2023012465A (es) 2024-04-04
EP4306541A3 (en) 2024-03-27
EP4306541A2 (en) 2024-01-17
AU2022260531A1 (en) 2023-11-30
IL307748A (en) 2023-12-01
US20230365698A1 (en) 2023-11-16
US20240360231A1 (en) 2024-10-31
US20240400699A1 (en) 2024-12-05
KR20250092298A (ko) 2025-06-23
AU2022260531A9 (en) 2023-12-07
CN120392997A (zh) 2025-08-01
SI4114465T1 (sl) 2023-11-30
PL4114465T3 (pl) 2024-04-08
JP2024102205A (ja) 2024-07-30
HUE063562T2 (hu) 2024-01-28
HRP20231255T1 (hr) 2024-02-02
PT4114465T (pt) 2023-11-03

Similar Documents

Publication Publication Date Title
CO2023015498A2 (es) Régimen de dosificación de anti-ifnar1 para inyección subcutánea
MX2025000105A (es) Inhibidor de kras g12c para el tratamiento del cancer
CL2021001288A1 (es) Heterociclos funcionalizados como agentes antivirales
DOP2020000050A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CO2019000069A2 (es) Agentes antivirales contra la hepatitis b
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
UY38059A (es) Heterociclos sustituidos como agentes antivirales
CL2021002747A1 (es) Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020)
UY37997A (es) Agentes antivirales contra la hepatitis b
UY38383A (es) Heterociclos funcionalizados como agentes antivirales
CR20140086A (es) Tratamientos de combinación para hepatitis c
MX388093B (es) Dosis y regimen para inhibidores de la interaccion hdm2-p53.
UY38948A (es) Régimen de dosificación para agentes anti-dll3
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
PE20190351A1 (es) Agente terapeutico del sindrome de hunter y metodo de tratamiento
AR119033A1 (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
PE20251599A1 (es) Metodos para el tratamiento de la obesidad
MX2021003606A (es) Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
MX2021008303A (es) Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa.
CL2025001708A1 (es) Esquema de dosificación de una dispersión sólida de un inhibidor de her2
MX2017005244A (es) Regimen de dosificacion para interferon pegilado.
AR125411A1 (es) Dosis
MX2025005408A (es) Método para proporcionar terapia con ecopipam a un paciente